{
  "id": 20610493,
  "title": "Kura Oncology at Jefferies Global Healthcare Conference: ziftomenib gains",
  "url": "https://urgent.news/2026/11/18/kura-oncology-at-jefferies-global-healthcare-conference-ziftomenib",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T15:09:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/kura-oncology-at-jefferies-global-healthcare-conference-ziftomenib-gains-93CH-5036515"
  },
  "original_language": "en",
  "account": "On November 18, 2026, Kura Oncology highlighted the strong early commercial traction of its lead menin inhibitor, ziftomenib, at the Jefferies Global Healthcare Conference. The drug is gaining market share and being used in combination therapy, with nearly 50% of patients receiving it alongside other treatments like venetoclax and azacitidine. Kura reported 150 new patient starts in the latest quarter, a 30% increase from the prior quarter, and total prescriptions up 60% quarter on quarter. The company has $490 million in cash and expects $180 million in milestone payments from Kyowa Kirin starting in 2026, funding operations and pipeline work through 2028 without another capital raise. Kura entered the market as a second mover and built its share by focusing on new patient starts and broader use across treatment settings. Clinical focus includes expanding patient reach and combination options, with phase 1B combination data in renal cell cancer expected in the second half of 2026 and early pancreatic ductal adenocarcinoma combination data also arriving in 2026.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}